Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 1/20 | 0.42 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | OGG1 | O15527 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6034394 | 0.81 | GABBR2 (0.42) | GABBR2GABBR1DPP4F2PRSS1 | |
| SCHEMBL6032624 | 0.81 | GABBR2 (0.64) | GABBR2GABBR1CA2CA1CYP1A2 | |
| SCHEMBL6033150 | 0.81 | GABBR2 (0.42) | GABBR2GABBR1CA2CA1ALOX5 | |
| SCHEMBL2486785 | 0.80 | GBA1 (0.49) | DPP4F2 | |
| SCHEMBL27721990 | 0.80 | GBA1 (0.49) | DPP4F2 | |
| SCHEMBL27662674 | 0.79 | GABBR2 (0.45) | GABBR2GABBR1CA2CA1CA9 | |
| SCHEMBL6034125 | 0.79 | GBA1 (0.48) | GABBR2GABBR1CA2CA1CA9 | |
| SCHEMBL28775527 | 0.77 | CYP2C19 (0.40) | GABBR2GABBR1CA2CA1HTR2A | |
| SCHEMBL18489359 | 0.77 | CYP1A2 (0.40) | GABBR2GABBR1CA2CA1CYP1A2 | |
| SCHEMBL28329064 | 0.77 | CYP1A2 (0.40) | GABBR2GABBR1CA2CA1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1882375-A | treatment of amyloid-and epileptogenesis-related diseases | NEUROCHEM INTERNAT LTD (CH) | 2006-12-20 | — | — | CN | disclosed |
| EP-1635909-A2 | TREATMENT OF AMYLOID- AND EPILEPTOGENESIS-ASSOCIATED DISEASES | Neurochem (International) Limited (CH) | 2006-03-22 | — | — | EP | disclosed |
| US-20050038000-A1 | Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2005-02-17 | — | — | US | disclosed |
| WO-2005000406-A2 | TREATMENT OF AMYLOID- AND EPILEPTOGENESIS-ASSOCIATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038000-A1 | Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases | APP, PSEN1, PSEN2 | GABBR2 203/4885GABBR1 144/4885DPP4 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.